Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevasemten in Becker Muscular Dystrophy (MESA)
NCT06066580Phase 2Enrolling by invitation
- Start
- Nov 2023
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of sevasemten in Becker muscular dystrophy (BMD). Started Nov 2023; status: enrolling by invitation.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT06066580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066580.